Markets:

Overview

News

Currencies

International

Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

2.408 -0.052 (-2.13%)

Streaming Delayed Price Updated: 2:25 PM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

March 22, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 15, 2023

Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET

From Context Therapeutics Inc.

Via GlobeNewswire

$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying ↗

February 22, 2023

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying ↗

February 14, 2023

The Dow Jones closed higher by more than 370 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Insiders Buying AmeriServ Financial And 2 Other Penny Stocks ↗

February 07, 2023

The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

February 06, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket ↗

February 01, 2023

Gainers

Via Benzinga

Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 31, 2023

Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr

Via Benzinga

Dow Surges Over 200 Points; Pfizer Issues Weak Forecast ↗

January 31, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P...

Via Benzinga

Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 31, 2023

Gainers

Via Benzinga

Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies ↗

January 31, 2023

Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received...

Via Benzinga

Dow Turns Higher; Nasdaq Jumps 100 Points ↗

January 31, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P...

Via Benzinga

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

January 31, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying ↗

January 31, 2023

The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying ↗

January 24, 2023

The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying ↗

January 19, 2023

The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

January 09, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

January 04, 2023

From Context Therapeutics Inc.

Via GlobeNewswire

Why Context Therapeutics Stock Is Falling 25% Today ↗

December 08, 2022

Context Therapeutics Inc (NASDAQ: CNTX) shares are trading lower by 26.62% to $1.02 during Thursday's session after the company reported preliminary Phase 2 data for ONA-XR metastatic breast cancer....

Via Benzinga

Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

December 08, 2022

Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.

Via Benzinga

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

December 08, 2022

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

November 29, 2022

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

November 21, 2022

Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented

From Context Therapeutics Inc.

Via GlobeNewswire

Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug ↗

November 10, 2022

Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.

Via Benzinga

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

November 09, 2022

From Context Therapeutics Inc.

Via GlobeNewswire

New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs ↗

August 17, 2022

Martin Lehr, Co-Founder and CEO of Contect Therapeutics, Inc (NASDAQ: CNTX), was a guest on Benzinga’s All Access on Aug 12, 2022.

Via Benzinga

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 03, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Via Benzinga

66 Biggest Movers From Friday ↗

May 23, 2022

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.

Via Benzinga

68 Biggest Movers From Yesterday ↗

April 05, 2022

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.